Mabion S.A. (WSE:MAB)

Poland flag Poland · Delayed Price · Currency is PLN
10.22
-0.16 (-1.54%)
May 12, 2025, 5:01 PM CET
-45.58%
Market Cap 165.18M
Revenue (ttm) 69.02M
Net Income (ttm) -6.33M
Shares Out 16.16M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 36,188
Average Volume 73,285
Open 10.40
Previous Close 10.38
Day's Range 10.22 - 10.46
52-Week Range 8.38 - 20.45
Beta 0.47
RSI 48.65
Earnings Date Apr 17, 2025

About Mabion

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 213
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MAB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.